https://www.yiliao.com/index.php?action=history&feed=atom&title=Neoantigens
Neoantigens - 版本历史
2026-04-18T13:25:48Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Neoantigens&diff=313650&oldid=prev
2026年1月8日 (四) 07:26 223.160.139.194
2026-01-08T07:26:31Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月8日 (四) 07:26的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l3" >第3行：</td>
<td colspan="2" class="diff-lineno">第3行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <del class="diffchange diffchange-inline"><strong></del>[[新抗原]]([[Neoantigens]])**是指由肿瘤细胞特有的基因突变（如非同义点突变、移码突变、染色体易位等）产生的全新蛋白质序列。由于这些抗原不在正常组织中表达，且未经过胸腺的免疫负向选择，因此具有极强的**[[免疫原性]]**，能被[[T细胞]]识别为“非己”成分。在当前的肿瘤免疫治疗格局中，[[新抗原]]是开发**[[个体化肿瘤疫苗]]**及**[[TCR-T细胞治疗]]**的核心靶标，被认为是实现“**[[肿瘤精准免疫]]**”的关键突破点。</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> [[新抗原]]([[Neoantigens]])**是指由肿瘤细胞特有的基因突变（如非同义点突变、移码突变、染色体易位等）产生的全新蛋白质序列。由于这些抗原不在正常组织中表达，且未经过胸腺的免疫负向选择，因此具有极强的**[[免疫原性]]**，能被[[T细胞]]识别为“非己”成分。在当前的肿瘤免疫治疗格局中，[[新抗原]]是开发**[[个体化肿瘤疫苗]]**及**[[TCR-T细胞治疗]]**的核心靶标，被认为是实现“**[[肿瘤精准免疫]]**”的关键突破点。</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l111" >第111行：</td>
<td colspan="2" class="diff-lineno">第111行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline"> </del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline"> </ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> [1] <strong>Sahin U, et al. (2017/Updated).</strong> <em>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.</em> <strong>[[Nature]]</strong>.<br></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> [1] <strong>Sahin U, et al. (2017/Updated).</strong> <em>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.</em> <strong>[[Nature]]</strong>.<br></div></td></tr>
</table>
223.160.139.194
https://www.yiliao.com/index.php?title=Neoantigens&diff=313648&oldid=prev
223.160.139.194：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-08T07:24:42Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[新抗原]]([[Neoantigens]])**是指由肿瘤细胞特有的基因突变（如非同义点突变、移码突变、染色体易位等）产生的全新蛋白质序列。由于这些抗原不在正常组织中表达，且未经过胸腺的免疫负向选择，因此具有极强的**[[免疫原性]]**，能被[[T细胞]]识别为“非己”成分。在当前的肿瘤免疫治疗格局中，[[新抗原]]是开发**[[个体化肿瘤疫苗]]**及**[[TCR-T细胞治疗]]**的核心靶标，被认为是实现“**[[肿瘤精准免疫]]**”的关键突破点。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">新抗原 (Neoantigens)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">肿瘤特异性抗原·TSA·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Neoantigen Presentation: Mutation-derived peptide binding to MHC</div><br />
</div><br />
[Schematic of somatic mutation resulting in neoepitope presentation]<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心属性：肿瘤特异性</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">来源</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">体细胞突变([[Somatic mutations]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键指标</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[TMB]](肿瘤突变负荷)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">识别分子</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[MHC]]/[[HLA]]复合物</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要应用</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">mRNA疫苗/TCR-T/TIL</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">筛选技术</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[NGS]]+AI算法预测</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">优势</th><br />
<td style="padding: 12px; color: #16a34a;">无脱靶毒性/突破免疫耐受</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">生成与识别机制：从突变到免疫应答</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[新抗原]]的免疫激活过程是一个多步骤的生物学瀑布流。其核心逻辑在于将细胞内部的遗传变异转化为细胞表面的免疫信号：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>遗传变异累积：</strong> 肿瘤细胞在演化过程中产生大量体细胞突变。其中，非同义突变会导致氨基酸序列改变，生成异质性肽段。</li><br />
<li style="margin-bottom: 12px;"><strong>抗原加工与呈递：</strong> 这些异质性蛋白质经[[蛋白酶体]]降解为 8-11个氨基酸的短肽，通过[[TAP]]转运体进入内质网，并与<strong>[[HLA]]</strong>（人类白细胞抗原）分子结合，呈递至细胞表面。</li><br />
<li style="margin-bottom: 12px;"><strong>TCR 识别与激活：</strong> 幼稚[[T细胞]]通过其表面的<strong>[[TCR]]</strong>（T细胞受体）特异性识别“新抗原-HLA”复合物。由于受试者体内缺乏针对这些新序列的免疫耐受，激活的 [[T细胞]] 能发起强力的针对性攻击。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">基于新抗原的临床治疗矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">治疗策略</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">技术核心</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床价值/前景</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[个体化mRNA疫苗]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">预测高亲和力新抗原序列，合成 mRNA 注入体内。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在[[黑色素瘤]]、[[胰腺癌]]术后辅助中展现推迟复发的显著潜力。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[TCR-T细胞疗法]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">筛选针对新抗原的优质 TCR，改造患者外周血 T 细胞。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">攻克实体瘤的关键武器；实现对胞内靶点的精准打击。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[TIL疗法]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">扩增肿瘤浸润淋巴细胞，其中富含识别新抗原的 T 细胞。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在[[黑色素瘤]]中已获 [[FDA]] 批准；新抗原反应性 TIL 是其效力核心。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">个体化新抗原筛选策略：从测序到预测</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[新抗原]]疗法的成功高度依赖于精准的筛选工作流，目前的行业标准包含：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>全外显子组测序([[WES]])：</strong> 对比肿瘤组织与配对正常细胞，识别体细胞单核苷酸变异（[[SNV]]）及插入缺失（[[Indels]]）。</li><br />
<li style="margin-bottom: 12px;"><strong>HLA 分型检测：</strong> 精确测定患者的 [[HLA-A/B/C]] 基因型，这是预测肽段结合力的前提。</li><br />
<li style="margin-bottom: 12px;"><strong>AI 深度学习预测：</strong> 利用算法（如[[NetMHCpan]]）模拟肽段与 [[HLA]] 的结合亲和力，并评估其在细胞表面的表达丰度及被 TCR 识别的可能性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[TMB]](肿瘤突变负荷)：</strong> 突变频率越高，产生可供识别的新抗原概率越大。</li><br />
<li style="margin-bottom: 8px;"><strong>[[dMMR/MSI-H]]：</strong> 错配修复缺陷导致的基因组高度不稳定，是新抗原产生的“天然温床”。</li><br />
<li style="margin-bottom: 8px;"><strong>[[个体化疫苗]]：</strong> 根据每位患者独特的突变图谱定制的“私人订制”治疗。</li><br />
<li style="margin-bottom: 8px;"><strong>[[肿瘤相关抗原]]([[TAA]])：</strong> 与新抗原相对，指在正常组织亦有表达但肿瘤中高发的抗原（易脱靶）。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Sahin U, et al. (2017/Updated).</strong> <em>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.</em> <strong>[[Nature]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项开创性研究证明了利用新抗原开发 mRNA 疫苗的临床可行性，奠定了现代肿瘤疫苗的基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Ott PA, et al. (2017/Updated).</strong> <em>An immunogenic personal neoantigen vaccine for patients with melanoma.</em> <strong>[[Nature]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：新抗原疗法的核心价值在于其极高的安全性，为晚期实体瘤的长程管理提供了全新维度。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
新抗原 (Neoantigens) 产业与技术 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[HLA-A0201]]•[[TCR]]•[[MHC-I/II]]•[[TAP1/2]]•[[Proteasome]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">代表药物/技术</td><br />
<td style="padding: 10px 15px; color: #334155;">[[mRNA-4157]]•[[BNT122]]•[[Lifileucel]]•[[TCR-T]]•[[DNA疫苗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[BioNTech]]•[[Moderna]]•[[SinoCellGene协作]]•[[Adaptimmune]]•[[Iovance]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿驱动</td><br />
<td style="padding: 10px 15px; color: #334155;">[[多肽结合力深度预测]]•[[公用新抗原筛查]]•[[ADC联合疫苗]]•[[三级淋巴结构诱导]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.139.194